FeNO by NIOX®
NIOX® develops and produces state-of-the-art technology for asthma diagnosis and management. Our aim is to improve the lives of millions of people suffering from asthma by helping physicians assess patients more accurately. Our market-leading device, NIOX VERO®, measures the level of fractional exhaled nitric oxide (FeNO) in the breath, with results proven to help with asthma treatment.1-3
NIOX® was the first to commercialise FeNO testing over 25 years ago. Today, we’re proud to say NIOX® remains the gold standard device4, with more than 50 million tests performed worldwide and counting. NIOX.com
References;
NIOX® was the first to commercialise FeNO testing over 25 years ago. Today, we’re proud to say NIOX® remains the gold standard device4, with more than 50 million tests performed worldwide and counting. NIOX.com
References;
- Carroll WD. NIOX VERO: Individualized Asthma Management in Clinical Practice. Pulmonary Therapy. 2016;2:171-88.
- Hanania NA et al. Measurement of fractional exhaled nitric oxide in real-world clinical practice alters asthma treatment decisions. Ann Allergy Asthma Immunol. 2018;120(4):414-418.
- Price DB et al. Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. Lancet Respir Med. 2018;6(1):29-39.
- NIOX®. Data on File; MKT-DOF-007. 2023.
 (1).png)
